Isolated myeloid-like bone marrow cell populations and methods of treatment therewith
US7931891B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 24, 2006 |
| Grant date | Apr 26, 2011 |
| Priority date | — |
| Expiry date | Feb 6, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2035/124
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides an isolated myeloid-like cell population comprising a majority of cells that are lineage negative, and which express both CD44 antigen, CD11b antigen, and hypoxia inducible factor 1 α (HIF-1 α). These cells have beneficial vasculotrophic and neurotrophic activity when intraocularly administered to the eye of a mammal, particularly a mammal suffering from an ocular degenerative disease. The myeloid-like cells are isolated by treating bone marrow cells, peripheral blood cells or umbilical cord cells with an antibody against CD44 (hyaluronic acid receptor), against CD11b, CD14, CD33, or against a combination thereof and using flow cytometry to positively select CD44 and/or CD11b expressing cells therefrom. The isolated myeloid-like bone marrow cells of the invention can be transfected with a gene encoding a therapeutically useful protein, for delivering the gene to the retina.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.